The stock of Nuvectis Pharma Inc (NVCT) has gone up by 1.95% for the week, with a 26.86% rise in the past month and a 20.62% rise in the past quarter. The volatility ratio for the week is 11.38%, and the volatility levels for the past 30 days are 7.44% for NVCT. The simple moving average for the past 20 days is 12.58% for NVCT’s stock, with a 9.41% simple moving average for the past 200 days.
Is It Worth Investing in Nuvectis Pharma Inc (NASDAQ: NVCT) Right Now?
Moreover, the 36-month beta value for NVCT is 0.44. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for NVCT is 7.65M and currently, short sellers hold a 13.68% of that float. On October 29, 2024, NVCT’s average trading volume was 108.26K shares.
NVCT) stock’s latest price update
Nuvectis Pharma Inc (NASDAQ: NVCT) has experienced a decline in its stock price by -10.50 compared to its previous closing price of 8.76. However, the company has seen a gain of 1.95% in its stock price over the last five trading days. businesswire.com reported 2024-10-28 that LONDON–(BUSINESS WIRE)—- $DRUG #Nasdaq–Nuvectis Pharma (NASDAQ: NVCT) is gaining momentum following recent presentations at the AACR-NCI-EORTC Symposium, where its SRC/YES1 inhibitor NXP900 demonstrated strong synergy with ALK inhibitors in NSCLC cells that despite being driven by ALK fusions, are resistant to treatment with the market leading ALK Inhibitors, alectinib (marketed by Roche) and lorlatinib (marketed by Pfizer). Meanwhile, NXP800, the company’s GCN2 activator, is progressing in a Phase 1b trial.
Analysts’ Opinion of NVCT
Many brokerage firms have already submitted their reports for NVCT stocks, with Ladenburg Thalmann repeating the rating for NVCT by listing it as a “Buy.” The predicted price for NVCT in the upcoming period, according to Ladenburg Thalmann is $21 based on the research report published on July 13, 2022 of the previous year 2022.
NVCT Trading at 15.78% from the 50-Day Moving Average
After a stumble in the market that brought NVCT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -35.21% of loss for the given period.
Volatility was left at 7.44%, however, over the last 30 days, the volatility rate increased by 11.38%, as shares surge +24.64% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +24.84% upper at present.
During the last 5 trading sessions, NVCT rose by +1.95%, which changed the moving average for the period of 200-days by -19.42% in comparison to the 20-day moving average, which settled at $6.96. In addition, Nuvectis Pharma Inc saw -6.00% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NVCT starting from BENTSUR RON, who purchase 1,940 shares at the price of $6.74 back on May 14 ’24. After this action, BENTSUR RON now owns 3,246,424 shares of Nuvectis Pharma Inc, valued at $13,076 using the latest closing price.
BENTSUR RON, the Chairman & CEO of Nuvectis Pharma Inc, purchase 2,000 shares at $6.40 during a trade that took place back on May 10 ’24, which means that BENTSUR RON is holding 3,244,484 shares at $12,800 based on the most recent closing price.
Stock Fundamentals for NVCT
Current profitability levels for the company are sitting at:
- 5.38 for the present operating margin
- 7.38 for the gross margin
The net margin for Nuvectis Pharma Inc stands at 5.15. The total capital return value is set at -1.76. Equity return is now at value -128.44, with -97.61 for asset returns.
Currently, EBITDA for the company is -22.9 million with net debt to EBITDA at 0.82. When we switch over and look at the enterprise to sales, we see a ratio of -31.24. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.17.
Conclusion
To wrap up, the performance of Nuvectis Pharma Inc (NVCT) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
